Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03145441|
Recruitment Status : Completed
First Posted : May 9, 2017
Last Update Posted : September 27, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
There are several factors initiating cytokine storm and dysregulated systemic inflammatory response during cardiac transplantation. This may lead to serious perioperative complications: circulatory collapse, respiratory insufficiency, acute renal and liver failure, multi-organ dysfunction etc.
On the other hand the high level of cytokines may play an important role in the development of graft rejection which is still a relevant problem in this patient group.
There are some new data showing that the use of extracorporeal cytokine adsorber during long cardiopulmonary bypass time (>120min) may be beneficial to prevent SIRS (Systemic Inflammatory Response Syndrome) with decreasing the level of cytokines in patients undergoing elective cardiac surgery. However there is lack of data and studies regarding the effect of extracorporeal cytokine adsorption during cardiac transplantation.
The aim of the study is to investigate the effect of extracorporeal cytokine adsorber built in the cardiopulmonary bypass circle during heart transplantation. The hypothesis is that removal of cytokines during heart transplantation prevents the development of extreme systemic inflammatory response, hemodynamic collapse dominated by vasoplegia, and contribute to reduce the incidence of severe perioperative complications and early graft rejection.
|Condition or disease||Intervention/treatment||Phase|
|Cardiac Transplantation Cardiopulmonary Bypass||Device: CytoSorb®||Not Applicable|
Patients undergoing cardiac transplantation will be enrolled in the study after giving a written, signed informed consent.
The participants will be randomized into two groups:
- intervention group (30 patients): a cytokine adsorber (CytoSorb®) will be installed into the cardiopulmonary bypass circle during the operation
- control group (30 patients): no cytokine adsorber will be used during cardiopulmonary bypass
The investigators will collect demographic, clinical and laboratory data about patients before, during and after the operation.
The the use of vasopressors and inotropes in the perioperative period, length of mechanical ventilation, ICU and hospital stay, and incidence of perioperative complications, early cellular or humoral graft rejection, and survival will be documented.
The level of cytokines (IL-1, IL-6, IL-10, IL-17, tumor necrosis factor-alfa) and complements before, during and after the use of cardiopulmonary bypass will be determined if the investigators find relevant difference between the two groups in clinical variables.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Impact of Pre-emptive Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation|
|Actual Study Start Date :||April 9, 2018|
|Actual Primary Completion Date :||December 31, 2021|
|Actual Study Completion Date :||December 31, 2021|
The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
No Intervention: Control
No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
- Early postoperative hemodynamic instability [ Time Frame: 24-48 hours ]
Hemodynamic instability described by Vasoactive Inotropic Score and calculated for the first two postoperative days.
Vasoactive Inotropic Score is considered as 'high' if values ≥ 30 points, representing higher risk for worse outcomes.
- Postoperative vasoplegia syndrome [ Time Frame: 24-48 hours ]Severity of postoperative vasoplegia based on criteria of vasoplegia syndrome: Norepinephrine reqirements ≥ 0.3 μg/kg/min AND arginine vasopressin requirements at any dose
- Cytokine and complement levels [ Time Frame: 24-48 hours ]Level of pro- and anti-inflammatory cytokines (IL-1, IL-6, IL-10, IL-17, tumor necrosis factor-alfa) and complements immediately after induction of anesthesia, before initiation of cardiopulmonary bypass (CPB), 2 hours after initiation of CPB, at termination of CPB, 6-12-24 hours after initiation of CPB
- Inflammatory reaction [ Time Frame: 24-48 hours ]Level of C reactive protein (CRP), white blood cells and procalcitonin immediately after induction of anesthesia, before initiation of cardiopulmonary bypass (CPB), 2 hours after initiation of CPB, at termination of CPB, 6-12-24 hours after initiation of CPB
- Mechanical ventilation [ Time Frame: up to 6 months ]Length of mechanical ventilation
- Hospital stay [ Time Frame: up to 6 months ]Length of ICU and hospital stay
- Length of survival [ Time Frame: 1 year ]Length of survival after heart transplantation
- Medical circulatory support [ Time Frame: 72 hours ]Use and dosage of vasopressors and inotropes immediately after induction of anesthesia, before initiation of cardiopulmonary bypass (CPB), 2 hours after initiation of CPB, at termination of CPB, 6-12-24 hours after initiation of CPB, on 2nd and 3rd postoperative day
- Perioperative complications [ Time Frame: up to 1 month ]Incidence of perioperative complications after heart transplantation during ICU stay (sepsis, SIRS, respiratory failure, acute renal failure, acute liver failure, postoperative cognitive dysfunction, graft failure)
- The incidence of early rejection [ Time Frame: 1 month ]The incidence of early (< 1 month) cellular or humoral rejection after heart transplantation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- patients undergoing heart transplantation
- no medical or mechanical circulatory support straight before transplantation
- age > 18 years
- age < 18 years
- septic condition (controlled infection) before transplantation
- prolonged hospital stay straight before transplantation
- use of positive inotropes or vasopressors straight before transplantation
- use of mechanical circulatory support straight before transplantation
- acute liver or kidney failure straight before transplantation
- high urgency transplantation
- the patient declines participating in the study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03145441
|Responsible Party:||Semmelweis University|
|Other Study ID Numbers:||
|First Posted:||May 9, 2017 Key Record Dates|
|Last Update Posted:||September 27, 2022|
|Last Verified:||September 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||Yes|
|Product Manufactured in and Exported from the U.S.:||Yes|